Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anna Wu
University of California Los Angeles, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImaginAB Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Wu has disclosed she is co-founder, an uncompensated Member of the Board, consultant and CSA and owns company stock which valued at (b)(4). She is also a co-inventor of intellectual property which will be further developed on this project. The Regents have patented UC case 2008-088 and have licensed it to ImaginAB. The Regents took equity in the licensing transaction with ImaginAB.
Multifunctional immunoPET tracers for pancreatic and prostate cancer
Prostate and pancreatic cancers are among the most common and difficult to treat cancers, with major challenges in accurately diagnosing and staging disease, as well as monitoring response to therapy. One major barrier to progress is the absence of effective molecular imaging tracers/tools that can guide patient management. Here we propose to develop novel cancer-specific molecular imaging agents based on engineered antibodies that recognize PSCA, a cell surface biomarker expressed in pancreatic and prostate cancer, to provide a disease-specific approach for imaging in newly diagnosed and recurrent disease, and to stratify patients at the molecular level in order to guide the use of both traditioal and targeted therapies.
Filed on June 12, 2013.
Tell us what you know about Anna Wu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Anna Wu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anna Wu | Beckman Research Institute/city of Hope | Conflict of Interest | ImaginAb, Inc. | $20,000 - $39,999 |
| Anna Wu | Beckman Research Institute/city of Hope | Conflict of Interest | ImaginAb, Inc. | $0 - $4,999 |
| Anna Wu | University of California Los Angeles | Conflict of Interest | ImaginAB Inc | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.